Aldeyra Therapeutics (ALDX) Price & Analysis

Compare

1,654 Followers

ALDX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.14 - $7.20

Previous CloseN/A

Volume102.94K

Average Volume (3M)1.25M

Market Cap

$309.06M

Enterprise Value$126.91M

Total Cash (Recent Filing)$90.06M

Total Debt (Recent Filing)$15.57M

Price to Earnings (P/E)―

Beta3.13

Next Earnings

Apr 30, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding59,895,588

10 Day Avg. Volume1,131,426

30 Day Avg. Volume1,250,123

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.41

Enterprise Value/Revenue518.99

Enterprise Value/Gross Profit-453.24K

Enterprise Value/Ebitda-2.29

Forecast

1Y Price Target

$8.75

Price Target Upside69.25% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

FDA Approval PotentialThe likelihood of FDA approval for Reproxalap is considered high, as it is seen as a differentiated DED drug with a disease-modifying mechanism.

Financial StabilityThe company ended the quarter with approximately $90 million in cash, which is considered sufficient to fund operations into 2027.

Partnership OpportunitiesIf approved, Abbvie is expected to opt in for a $200M partnership, which is crucial for gaining patient access and reimbursement in the competitive DED space.

Bears Say

Investor SentimentInvestors are skeptical of the approval of reproxalap in dry eye disease based solely on a positive resubmission chamber trial, as the stock is down.

Regulatory ChallengesIt's difficult not to be a little skeptical given the saga with this development program and the continuous issues that the FDA keeps bringing up even when management thinks everything is OK.

Trial Variability ConcernsThe failure of the field trial, attributed to variability related to temperature, humidity, and pollen, accompanied the positive second resubmission chamber trial.

Aldeyra Therapeutics News

Aldeyra receives orphan designation for ADX-2191 from EMA

Aldeyra (ALDX) announced that the European Medicines Agency has granted orphan designation for ADX-2191 for the treatment of...

15d ago

ALDX

Aldeyra announces FDA acceptance for review of reproxalap NDA

Aldeyra (ALDX) announced that the FDA has accepted for review the resubmitted new drug application for topical ocular...

22d ago

ALDX

FDA Accepts Aldeyra’s Reproxalap Application for Review

Aldeyra Therapeutics ( ($ALDX) ) has provided an update. On July 17, 2025, Aldeyra Therapeutics announced that the...

22d ago

ALDX

Aldeyra Therapeutics: Positioned for Success with ADX-2191 and Strategic Portfolio Expansion

BTIG analyst Thomas Shrader has maintained their bullish stance on ALDX stock, giving a Buy rating yesterday. Thomas...

1M ago

ALDX

Aldeyra Therapeutics Receives FDA Protocol Agreement for ADX-2191

Aldeyra Therapeutics ( ($ALDX) ) has shared an announcement. On June 26, 2025, Aldeyra Therapeutics announced that it...

1M ago

ALDX

Aldeyra receives special protocol assessment agreement letter from FDA

Aldeyra (ALDX) announced receipt of a special protocol assessment agreement letter from the FDA for ADX-2191, an investigational...

1M ago

ALDX

Aldeyra Therapeutics: Buy Rating Affirmed Amidst Promising Developments in Dry Eye Disease Treatment and Strategic Partnerships

In a report released on June 18, Thomas Shrader from BTIG maintained a Buy rating on Aldeyra Therapeutics...

2M ago

ALDX

Aldeyra Resubmits Reproxalap NDA to FDA

An update from Aldeyra Therapeutics ( ($ALDX) ) is now available. On June 17, 2025, Aldeyra Therapeutics announced...

2M ago

ALDX

Aldeyra resubmits topical ocular reproxalap NDA to FDA

Aldeyra (ALDX) announced the resubmission of a new drug application to the FDA for topical ocular reproxalap, an...

2M ago

ALDX

Aldeyra Therapeutics Holds Annual Meeting with Key Votes

Aldeyra Therapeutics ( ($ALDX) ) just unveiled an update. At the Aldeyra Therapeutics annual meeting held on June...

2M ago

ALDX

Aldeyra Therapeutics: Strong Financial Position and Positive Trial Outcomes Drive Buy Rating

Aldeyra Therapeutics (ALDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on...

3M ago

ALDX

Aldeyra Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Strategic Partnerships

Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Buy rating on Aldeyra Therapeutics (ALDX – Research Report)....

3M ago

ALDX

Aldeyra Therapeutics: Buy Rating Backed by Promising Trial Results and Strategic Opportunities

Leerink Partners analyst Marc Goodman has maintained their bullish stance on ALDX stock, giving a Buy rating yesterday....

3M ago

ALDX

Buy Rating for Aldeyra Therapeutics Driven by Reproxalap’s Promising Phase 3 Results and Strategic Partnership Potential with AbbVie

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Aldeyra Therapeutics (ALDX – Research Report) today and...

3M ago

ALDX

ALDX FAQ

What was Aldeyra Therapeutics’s price range in the past 12 months?

Aldeyra Therapeutics lowest stock price was $1.14 and its highest was $7.20 in the past 12 months.

What is Aldeyra Therapeutics’s market cap?

Aldeyra Therapeutics’s market cap is $309.06M.

When is Aldeyra Therapeutics’s upcoming earnings report date?

Aldeyra Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 265 days.

How were Aldeyra Therapeutics’s earnings last quarter?

Currently, no data Available

Is Aldeyra Therapeutics overvalued?

According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aldeyra Therapeutics pay dividends?

Aldeyra Therapeutics does not currently pay dividends.

What is Aldeyra Therapeutics’s EPS estimate?

Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aldeyra Therapeutics have?

Aldeyra Therapeutics has 59,895,588 shares outstanding.

What happened to Aldeyra Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Aldeyra Therapeutics?

Currently, no hedge funds are holding shares in ALDX

Aldeyra Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-65.19%

Trailing 12-Months

Asset Growth

-34.04%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Aldeyra Therapeutics (ALDX) Earnings & Revenues

Historic Earnings Reports

ALDX Stock 12 Month Forecast

Average Price Target

$8.75

▲(69.25% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","3.5":"$3.5","8.5":"$8.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.5,6,8.5,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.12,2.726153846153846,3.332307692307692,3.9384615384615387,4.544615384615385,5.150769230769231,5.756923076923077,6.363076923076923,6.969230769230769,7.575384615384616,8.181538461538462,8.787692307692307,9.393846153846155,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.12,2.63,3.14,3.6500000000000004,4.16,4.67,5.18,5.69,6.2,6.71,7.22,7.73,8.24,{"y":8.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.12,2.4184615384615387,2.716923076923077,3.0153846153846153,3.313846153846154,3.6123076923076924,3.9107692307692306,4.2092307692307696,4.507692307692308,4.806153846153846,5.104615384615385,5.403076923076923,5.701538461538462,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.86,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.22,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.27,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.29,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.82,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.99,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >